Table 1

Baseline demographics and clinical characteristics of all analysed SSc patients (N=63)

Baseline characteristics (N=63)
Age (years) mean±SEMN=63; 50.9±1.6
Scleroderma subtype
Disease duration in years median (IQR)N=60; 6 (3–11)
Follow-up in months (IQR)7 (4–9)
Autoantibodies positiven/N(%)
 Anti-RNA polymerase III3/525.8
  • Autoantibodies were measured and interpreted according to local standards. Demographics and clinical characteristics are defined according to EUSTAR criteria.30

  • ACA, anticentromere antibody; anti-Scl 70, antitopoisomerase 1 antibody; anti-U1-snRNP, anti-U1 small nuclear ribonucleoprotein antibody; EUSTAR, European Scleroderma Trial and Research; N, number of patients available for analysis; n, number of patients with the specific feature; SSc, systemic sclerosis.